We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Generic Companies Consider Conducting Phase IV Trials
Generic Companies Consider Conducting Phase IV Trials
August 21, 2007
The FDA has sent a letter to companies that hold approved applications for midodrine hydrochloride informing them that since the new drug application (NDA) holder, Shire, has not completed postmarketing study requirements, the NDA and all abbreviated new drug applications (ANDAs) are subject to withdrawal.